Get the Daily Brief

All action, no filler. BioBriefs delivers the industry’s 10 must-know updates, every morning.

Latest Biotech News

Legend’s off-the-shelf CAR T moves toward outpatient dosing

June 15, 2026

Legend Biotech USA presented updated first-in-human CAR T data for LB-2501 at EHA2026, positioning the CD19/CD20 dual-targeting therapy as a potential first-in-class, off-the-shelf option that...

Rocket Pharma sells FDA priority review voucher to fund rare disease pipeline

June 15, 2026

Rocket Pharmaceuticals said it raised $180 million by selling an FDA drug review fast pass tied to an accelerated approval for Kresladi, a rare pediatric disease priority review voucher. Rocket...

Biotech IPO surge continues with Parabilis’ record listing

June 15, 2026

Parabilis Medicines set a new Wall Street biotech IPO record by pricing its offering at $20 per share and raising $770.5 million in gross proceeds, according to IPO coverage. The company’s upsized...

Moderna and CEPI accelerate Bundibugyo mRNA Ebola vaccine toward phase 1

June 15, 2026

Moderna is pushing an investigational mRNA vaccine against the Bundibugyo virus species linked to the ongoing Ebola outbreak in the Democratic Republic of the Congo and Uganda. The program...

Cell therapy innovation: partial reprogramming gene therapy treated first patient in glaucoma trial

June 15, 2026

Life Biosciences announced it has treated the first participant in a gene therapy trial aiming to partially reprogram aged cells to a younger-like state. The approach turns on three genes intended...

Mid-stage funding: HMNC Brain Health raises to advance two depression drugs

June 15, 2026

HMNC Brain Health raised $50 million in a Series B round to advance two psychiatry programs into mid-stage studies. Medice led the financing, with additional support from other backers,...

Diagnostic genomics adoption: Netherlands pushes long-read sequencing as first-tier test

June 15, 2026

Researchers from the Netherlands reported at ESHG that long-read genome sequencing as a first-tier diagnostic test may not substantially increase diagnostic yield versus short-read testing, but it...

Cancer therapeutics biology: YBX1 drives immune evasion in NSCLC bone metastases

June 15, 2026

New research identified Y-box binding protein 1 (YBX1) as a driver of immune-evasive features in non-small cell lung cancer bone metastases, laying groundwork for potential targeted strategies in...

Precision oncology prediction: integrating genetic origin data with tumor mutations improves survival forecasts

June 15, 2026

Researchers presented findings suggesting that a patient’s genetic ancestry can materially influence cancer progression and survival predictions when integrated with tumor analysis. The work,...

Psoriasis—Phase 3 readout and potential FDA filing

June 15, 2026

Takeda reported head-to-head Phase 3 results for its AI-designed oral psoriasis drug zasocitinib, claiming complete skin clearance in more than 35% of patients at 16 weeks. The company said the...

Ebola—CEPI-backed mRNA push for Bundibugyo outbreak

June 15, 2026

Moderna and CEPI moved to accelerate development of an mRNA vaccine targeting the Bundibugyo virus species driving the current Ebola outbreak in the Democratic Republic of the Congo and Uganda....

Cell therapy—outpatient CAR T concept data at EHA

June 15, 2026

Legend Biotech’s CD19/CD20 dual-target CAR T LB-2501 posted first-in-human updates at EHA2026 that aim to support development as an off-the-shelf, single-infusion, outpatient CAR T approach....

Biotech capital markets—record IPO prices and raises

June 15, 2026

Parabilis Medicines set a new U.S. biotech IPO record by pricing its offering and raising gross proceeds of $770.5 million after an upsized launch. The company entered Nasdaq trading at the high...

Biotech policy and security oversight—US-funded global biolabs evidence

June 15, 2026

ODNI Director Tulsi Gabbard released declassified information asserting evidence of U.S. taxpayer funding for more than 120 biolabs across over 30 countries. The ODNI release claims the...

Rare disease gene therapy finance—priority review voucher monetization

June 15, 2026

Rocket Pharmaceuticals sold an FDA drug review fast pass tied to the accelerated approval of Kresladi for a rare pediatric indication, securing $180 million in non-dilutive capital. Rocket said...

Aging and safety signals—GLP-1 associated hypotensive events

June 15, 2026

Northwestern Medicine researchers reported a safety concern tied to glucagon-like peptide-1 receptor agonists, linking GLP-1 use to higher rates of fainting and dizziness. The analysis focused on...

Metabolic drug outcomes—semaglutide and fracture risk

June 15, 2026

Stanford University researchers reported retrospective cohort findings suggesting semaglutide is associated with a reduced risk of bone fractures. The analysis used electronic health record data...

Genomics diagnostics—first-tier long-read sequencing rollout

June 15, 2026

Implementation data from the Netherlands suggest long-read genome sequencing can streamline rare-disease diagnostics when used as a first-tier test. Presenters at the European Society of Human...

Renal transplant pharmacogenomics—genetics-guided tacrolimus dosing

June 15, 2026

A 2026 study in BMC Pharmacology and Toxicology reported that CYP3A5 genetic variability can be used to tailor tacrolimus dosing in pediatric renal transplant patients. The work focused on...

Semaglutide safety signals tied to bone outcomes

June 14, 2026

Semaglutide use was associated with a reduced risk of bone fractures in a large retrospective cohort study using data from more than 161 million patients across U.S. hospitals and academic...